Fullerton Fund Management’s Novartis NVS Stock Holding History

Fullerton Fund Management’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,692	Closed	-$246K	–	87
2021 Q2	$246K	Sell	2,692 -1,548	-37%	-$138K	0.02%	75
2021 Q1	$362K	Sell	4,240 -1,056	-20%	-$94.8K	0.03%	68
2020 Q4	$500K	Buy	5,296 +3,243	+158%	+$283K	0.04%	71
2020 Q3	$179K	Buy	+2,053	New	+$178K	0.02%	66

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Aristotle Capital Management Los Angeles, California $47.8B AUM 13.38% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Fullerton Fund Management's NVS Position: Q3 2021 in Review

Fullerton Fund Management sold out of Novartis (NVS) in Q3 2021, closing a stake of 2,692 shares — an estimated $246K sold.

Fullerton Fund Management first reported a position in NVS in Q3 2020 and held it in 4 quarters. The position peaked at $500K in Q4 2020. 1,080 funds tracked by Wall St. Rank hold NVS as of Q3 2021.

Fullerton Fund Management reported no remaining Novartis position as of Q3 2021 after selling out during the quarter.
Fullerton Fund Management sold 2,692 Novartis shares in Q3 2021, an estimated $246K.
Fullerton Fund Management first reported a position in Novartis in Q3 2020 and held it in 4 quarters.
Fullerton Fund Management's Novartis position peaked at $500K in Q4 2020.
1,080 funds tracked by Wall St. Rank held Novartis as of Q3 2021.

Based on Fullerton Fund Management's 13F filing for Q3 2021, filed 15 Nov 2021.